iShares China Large-Cap ETF vs Guardant Health Inc. Common Stock — how do they compare? iShares China Large-Cap ETF trades at $34.22 (market cap $3.86B), while Guardant Health Inc. Common Stock trades at $168.65 (market cap $22.22B). The key difference: Guardant Health Inc. Common Stock is far larger — about 5.8× iShares China Large-Cap ETF's market cap, and Guardant Health Inc. Common Stock is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 149 Days and Guardant Health Inc. Common Stock for 0 Days on average.
| FXI | GH | |
|---|---|---|
Market Cap | $3.86B | $22.22B |
Volume | 16,323,837 | 1,589,453 |
52-Week High | $41.08 | $187.22 |
52-Week Low | $31.59 | $61.73 |
Typical Hold Time | 149 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $22.86B |
Signals from Pluang's Aura AI — not financial advice
FXI (iShares China Large-Cap ETF) trades at $34.30, up 2.63% on the day, but technical indicators signal a bearish trend with 17 sell signals versus 1 buy. The ETF faces headwinds from China's economic challenges and geopolitical tensions, though some analysts highlight its attractive valuation at half the S&P 500's P/E ratio. Recent news focuses on U.S.-China relations and export dynamics.
The outlook remains cautious due to China's industrial overcapacity and weak domestic consumption. While valuation appears compelling, political risks and technical weakness suggest limited near-term upside. Investors should weigh the discount against ongoing macroeconomic pressures in China.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →